November 8, 2024 – InventisBio’s KRAS G12C Inhibitor Anfangning (Garsorasib, D-1553) Receives Market Authorization from the National Medical Products Administration (NMPA) of China Anfangning (Garsorasib), a KRAS G12C inhibitor developed by InventisBio, has been officially approved by the National Medical Products Administration (NMPA) of China for the treatment of adult patients with advanced non-small cell…

2024 World Lung Cancer Conference (WCLC) | Latest Progress of Garsorasib (D-1553) in Treating KRAS G12C-Mutant Non-Small Cell Lung Cancer: Phase 2 Study Updates The 2024 World Lung Cancer Conference (WCLC) was held from September 7 to 10 in San Diego, USA. During the event, Professor Li Ziming from Shanghai Chest Hospital presented the latest…

Recently, Garsorasib (D-1553), developed by InventisBio, has been once again included in the Breakthrough Therapy Designation (BTD) program by the National Medical Products Administration (NMPA). This time, two new indications for D-1553 have been added to the BTD program: For the treatment of locally advanced or metastatic pancreatic ductal adenocarcinoma (PDAC) with KRAS G12C mutation,…

On June 11, 2024, the Phase II study results of Garsorasib (D-1553) for KRAS G12C-mutant non-small cell lung cancer (NSCLC) were published in The Lancet Respiratory Medicine, one of the world’s most prestigious medical journals (Impact Factor: 76.2). This study, conducted in China, highlighted the promising efficacy and safety profile of Garsorasib, marking it as…

InventisBio will present the latest Phase II clinical trial data of Garsorasib (D-1553) in KRAS G12C-mutant non-small cell lung cancer (NSCLC) patients at the 2024 American Association for Cancer Research (AACR) Annual Meeting. This marks the second major international conference appearance for this study (NCT05383898), following its presentation at the 2022 World Lung Cancer Conference…